Evaluation of an antibody that inhibits thrombosis without causing bleeding

Thrombosis remains a major cause of death and morbidity worldwide. Existing antithrombotics reduce clotting but also increase bleeding, limiting their use. No agents approved for marketing or in clinical trials have been shown to significantly dissociate this bleeding risk from the degree of antithrombosis. This project relates to the initial manufacture and pre-clinical assessment of ichorcumab, a monoclonal antibody against the exosite 1 region of thrombin that is based on an antibody serendipitously discovered in a patient found to be completely anticoagulated but with no observed increase in bleeding risk - the ideal clinical profile. Ichorcumab has the potential to be the first drug to deliver antithrombosis without bleeding, making antithrombosis safer and more effective, and extending antithrombosis to new indications.